transactlat - risultati della ricerca

devatis ag - ambrisentanum - compresse rivestite con film - filmtablette: ambrisentanum 5 mg, lactosum monohydricum 70.725 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 187 µg, magnesii stearas, Überzug: poly(alcohol vinylicus), talcum, macrogolum 3350, lecithinum ex soja, e 171, e 129 42.3 µg, pro compresso obducto. - polmonare ipertensione arteriosa - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

ambrisentan devatis 10 mg compresse rivestite con film

devatis ag - ambrisentanum - compresse rivestite con film - filmtablette: ambrisentanum 10 mg, lactosum monohydricum 141.45 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 374 µg, magnesii stearas, Überzug: poly(alcohol vinylicus), talcum, macrogolum 3350, lecithinum ex soja, e 171, e 129 354 µg, pro compresso obducto. - polmonare ipertensione arteriosa - synthetika

Unione Europea - italiano - EMA (European Medicines Agency)

lenalidomide mylan

mylan ireland limited - lenalidomide - mieloma multiplo - immunosoppressori - multiple myelomalenalidomide mylan as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide mylan as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. lenalidomide mylan in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide mylan in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1-3a).